ArticleHypertension (Dallas, Tex. : 1979)2009
Intrarenal dopamine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway.
Article in Hypertension (Dallas, Tex. : 1979), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Renalase, dopamine, and norepinephrine as markers for the development of hypertension in CKD patients.BMC nephrology · 2025Article
- The Role of the EGF Receptor in Sex Differences in Kidney Injury.Journal of the American Society of Nephrology : JASN · 2019Article
- Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation.The pharmacogenomics journal · 2019Review
- Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity.Hypertension (Dallas, Tex. : 1979) · 2018Article
- Article
- Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control.JCI insight · 2018Article
- Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.Journal of the American Society of Nephrology : JASN · 2017Article
- Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension.The Journal of clinical investigation · 2015Article
- p47(phox) contributes to albuminuria and kidney fibrosis in mice.Kidney international · 2015Article
- Antihypertensive mechanisms of intra-renal dopamine.Current opinion in nephrology and hypertension · 2015Review
- Renal dopamine receptors, oxidative stress, and hypertension.International journal of molecular sciences · 2013Review
- Upregulation of renal D5 dopamine receptor ameliorates the hypertension in D3 dopamine receptor-deficient mice.Hypertension (Dallas, Tex. : 1979) · 2013Article
- Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney.Transactions of the American Clinical and Climatological Association · 2013Article
- Diagnostic tools for hypertension and salt sensitivity testing.Current opinion in nephrology and hypertension · 2013Review
- Article
- Dopamine, the kidney, and hypertension.Current hypertension reports · 2012Review
- Potential dopamine-1 receptor stimulation in hypertension management.Current hypertension reports · 2011Review
- Dopamine and renal function and blood pressure regulation.Comprehensive Physiology · 2011Review
- Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice.The Journal of clinical investigation · 2011Article
- Genetics of salt-sensitive hypertension.Current hypertension reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Locally produced dopamine in the renal proximal tubule inhibits salt and fluid reabsorption, and a dysfunctional intrarenal dopaminergic system has been reported in essential hypertension and experimental hypertension models. Using catechol-O-methyl-transferase knockout (COMT(-/-)) mice, which have increased renal dopamine because of deletion of the major renal dopamine-metabolizing enzyme, we investigated the effect of intrarenal dopamine on the development of hypertension in the deoxycorticosterone acetate/high-salt (DOCA/HS) model. DOCA/HS led to significant increases in systolic blood pressure in wild-type mice (from 115+/-2 to 153+/-4 mm Hg), which was significantly attenuated in COMT(-/-) mice (from 114+/-2 to 135+/-3 mm Hg). In DOCA/HS COMT(-/-) mice, the D1-like receptor antagonist SCH-23390 increased systolic blood pressure (156+/-2 mm Hg). DOCA/HS COMT(-/-) mice also exhibited more urinary sodium excretion (COMT(-/-) versus wild-type: 3038+/-430 versus 659+/-102 micromol/L per 24 hours; P<0.01). Furthermore, DOCA/HS-induced renal oxidative stress was significantly attenuated in COMT(-/-) mice. COX-2-derived prostaglandins in the renal medulla promote sodium excretion, and dopamine stimulates medullary prostaglandin production. Renal medullary COX-2 expression and urinary prostaglandin E2 excretion were significantly higher in COMT(-/-) than in wild-type mice after DOCA/HS treatment. In DOCA/HS-treated COMT(-/-) mice, the COX-2 inhibitor SC-58236 reduced urinary sodium and prostaglandin E(2) excretion and increased systolic blood pressure (153+/-2 mm Hg). These studies indicate that an activated renal dopaminergic system attenuates the development of hypertension, at least in large part through activating medullary COX-2 expression/activity, and also decreases oxidative stress resulting from DOCA/HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.